Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of NS-089/NCNP-02 in Duchenne muscular dystrophy
jRCT2031210162Phase 2Active, not recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brogidirsen in Duchenne muscular dystrophy (DMD), sponsored by Nippon Shinyaku. Primary endpoint: Adverse events and adverse drug reactions. Started Jun 2021; status: active, not recruiting.
02
Drugs
brogidirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2031210162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210162.